Santhera, Biovail in $192M Pact for Parkinson's Drug Fipamezole

One week after securing its ownership of the Parkinson's drug fipamezole, Santhera Pharmaceuticals Holding AG secured a partner for the compound, in the shape of Biovail Corp., which could end up paying the Swiss firm as much as $192 million in up-front, development, regulatory and commercial milestones for North American rights to the drug. (BioWorld Today)